Suchergebnisse - "Tarantino, Paolo"

PubPharm (120)

1

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

enthalten in: NPJ breast cancer | 2024

von Tarantino, P. | Leone, J. | Vallejo, C. | +9

2

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer : the OXEL randomized phase II study

enthalten in: Nature communications | 2024

von Lynce, F. | Mainor, C. | Donahue, R. | +26

UpdateOf: medRxiv. 2023 Dec 04;:. - PMID 38105958

3

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Tarantino, P. | Ajari, O. | Graham, N. | +11

4

Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy) : a matter of preventive health

enthalten in: Oncotarget | 2024

von De Matteis, E. | Tumolo, M. | Tarantino, P. | +6

5

Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience

enthalten in: The oncologist | 2024

von Crimini, E. | Tini, G. | Tarantino, P. | +12

6

Immunotherapy for Early-Stage Triple Negative Breast Cancer : Is Earlier Better?

enthalten in: Current oncology reports | 2024

von Song, F. | Tarantino, P. | Garrido-Castro, A. | +3

7

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents

enthalten in: The oncologist | 2024

von Nicolò, E. | Tarantino, P. | D'Ecclesiis, O. | +18

8

Author Correction : Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

enthalten in: Nature communications | 2023

von Tarantino, P. | Gupta, H. | Hughes, M. | +24

ErratumFor: Nat Commun. 2023 Nov 18;14(1):7496. - PMID 37980405

9

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

enthalten in: bioRxiv.org | 2023

von Lynce, F. | Mainor, C. | Donahue, R. | +26

10

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer : the OXEL randomized phase II study

enthalten in: medRxiv : the preprint server for health sciences | 2023

von Lynce, F. | Mainor, C. | Donahue, R. | +26

UpdateIn: Nat Commun. 2024 Mar 27;15(1):2691. - PMID 38538574

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]